Arizona State Retirement System Has $696,000 Stake in Progyny, Inc. (NASDAQ:PGNY)

Arizona State Retirement System increased its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 2.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,313 shares of the company’s stock after purchasing an additional 609 shares during the period. Arizona State Retirement System’s holdings in Progyny were worth $696,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Progyny by 0.5% during the first quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock worth $317,097,000 after buying an additional 41,687 shares in the last quarter. Jennison Associates LLC raised its stake in Progyny by 2.7% in the 1st quarter. Jennison Associates LLC now owns 2,596,422 shares of the company’s stock worth $99,054,000 after purchasing an additional 67,632 shares in the last quarter. Principal Financial Group Inc. raised its stake in Progyny by 3.1% in the 1st quarter. Principal Financial Group Inc. now owns 1,400,701 shares of the company’s stock worth $53,437,000 after purchasing an additional 42,302 shares in the last quarter. Congress Asset Management Co. MA boosted its holdings in Progyny by 11.8% in the 1st quarter. Congress Asset Management Co. MA now owns 1,009,483 shares of the company’s stock valued at $38,512,000 after purchasing an additional 106,574 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Progyny by 14.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 844,679 shares of the company’s stock worth $31,406,000 after purchasing an additional 105,544 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Trading Up 3.9 %

Shares of Progyny stock opened at $24.15 on Monday. The firm’s 50 day moving average is $24.77 and its 200 day moving average is $29.06. The firm has a market capitalization of $2.30 billion, a PE ratio of 39.59, a price-to-earnings-growth ratio of 1.86 and a beta of 1.45. Progyny, Inc. has a 1 year low of $19.60 and a 1 year high of $42.08.

Progyny (NASDAQ:PGNY) last posted its earnings results on Tuesday, August 6th. The company reported $0.17 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.17. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The firm had revenue of $304.09 million for the quarter, compared to analysts’ expectations of $305.32 million. During the same quarter in the previous year, the firm posted $0.15 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. As a group, research analysts anticipate that Progyny, Inc. will post 0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $37.00 price target on shares of Progyny in a research note on Tuesday, August 20th. JPMorgan Chase & Co. cut their target price on Progyny from $41.00 to $31.00 and set an “overweight” rating for the company in a research report on Monday, August 19th. Leerink Partners cut Progyny from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $31.00 to $25.00 in a research report on Wednesday, August 7th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $24.00 price objective (down previously from $37.00) on shares of Progyny in a research report on Wednesday, August 7th. Finally, JMP Securities decreased their target price on shares of Progyny from $36.00 to $31.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $31.90.

Insider Buying and Selling at Progyny

In other news, President Michael E. Sturmer sold 9,030 shares of Progyny stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total transaction of $270,900.00. Following the sale, the president now directly owns 362,583 shares of the company’s stock, valued at $10,877,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, President Michael E. Sturmer sold 9,030 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the completion of the transaction, the president now owns 362,583 shares of the company’s stock, valued at $10,877,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Scott sold 1,462 shares of the business’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $28.39, for a total transaction of $41,506.18. Following the completion of the sale, the director now directly owns 10,098 shares in the company, valued at approximately $286,682.22. The disclosure for this sale can be found here. Corporate insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.